A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC

Clinical trial NCT04521075 · UNKNOWN

Trial details

NCT number: NCT04521075
Sponsor: Ella Therapeutics Ltd
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Melanoma Stage IV Unresectable Melanoma NSCLC Stage IV

Start date: 2020-11-01
Primary completion: 2022-07-01
Enrollment: 42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.